Axon Enterprise, Inc (NASDAQ:AXON) Holdings Raised by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC grew its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 82.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,607 shares of the biotechnology company's stock after acquiring an additional 724 shares during the quarter. Kingswood Wealth Advisors LLC's holdings in Axon Enterprise were worth $867,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock valued at $5,019,886,000 after acquiring an additional 275,959 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Axon Enterprise by 3.7% in the 4th quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock valued at $1,095,542,000 after acquiring an additional 65,097 shares during the last quarter. Capital World Investors increased its holdings in shares of Axon Enterprise by 86.4% in the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after acquiring an additional 841,772 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Axon Enterprise by 273.8% in the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after acquiring an additional 812,337 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Axon Enterprise in the 4th quarter valued at approximately $482,081,000. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON traded up $6.53 on Friday, hitting $777.32. The company's stock had a trading volume of 1,181,999 shares, compared to its average volume of 476,402. Axon Enterprise, Inc has a 12 month low of $279.02 and a 12 month high of $806.64. The company has a market capitalization of $60.51 billion, a price-to-earnings ratio of 187.76, a price-to-earnings-growth ratio of 89.48 and a beta of 1.29. The stock's 50-day moving average is $692.15 and its two-hundred day moving average is $625.71. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.62 and a current ratio of 2.83.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. During the same quarter in the prior year, the business posted $1.15 earnings per share. The company's revenue for the quarter was up 31.3% compared to the same quarter last year. On average, equities research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AXON. Bank of America boosted their price target on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday, June 4th. Barclays upped their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. The Goldman Sachs Group upped their price objective on Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Craig Hallum downgraded Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Finally, Needham & Company LLC upped their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $699.55.

Insider Transactions at Axon Enterprise

In other news, CFO Brittany Bagley sold 3,400 shares of the company's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the sale, the chief financial officer now owns 131,833 shares in the company, valued at $92,283,100. This represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, President Joshua Isner sold 905 shares of the company's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total value of $702,632.95. Following the completion of the sale, the president now owns 268,735 shares of the company's stock, valued at approximately $208,643,166.65. This trade represents a 0.34% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,642 shares of company stock valued at $30,500,428. 4.40% of the stock is currently owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.